View Older Stories View More Recent Stories
-
Evercore ISI on Gilead (GILD): 'Gilead isn’t hyping it etc, the conversation flow was us reaching out to Gilead to clarify, rather than Gilead flagging it to everyone'
-
Amgen 'encouraged' by weight-loss drug interim data, shares jump
-
Evercore ISI Downgrades Amylyx Pharmaceuticals inc. (AMLX) to In Line
-
Evercore ISI Starts Fractyl Health Inc (GUTS) at Outperform
-
Frontier Medicines to Participate in Upcoming Investor Conferences
-
Evercore ISI Starts Rapt Therapeutics (RAPT) at Outperform, 'risk reward is very good at these levels'
-
Pharma price cut proposals from US government could be steep, analysts say
-
Gilead drops 11% after lung cancer drug trial fails, analyst says stock is 'overreacting'
-
Analyst says buy the pullback in obesity stocks as today's report refers to old data
-
Evercore ISI Recognized as the Top-Ranked Firm in U.S. Equity Research for the Second Consecutive Year
-
Evercore ISI Upgrades Alkermes (ALKS) to Outperform, 'down 10%? I wouldn’t have thought so'
-
Around 1.8 million Americans received COVID shots last week -IQVIA
-
Evercore ISI Remains Positive on Apellis Pharmaceuticals (APLS)
-
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
-
Evercore ISI on Pfizer (PFE): 'Hard to ignore the d-dimer findings with Pfizer TFPI'
-
Evercore ISI Upgrades Teva Pharma (TEVA) to Outperform, 'TL1A & pipeline in focus'
-
Evercore's DiFiore on Amylyx Pharmaceuticals inc. (AMLX) ALS Relyvrio Launch: 'I feel very confident in launch and remain very constructive'
-
Evercore ISI Says Gilead Sciences (GILD) Tenofovir Risk 'waning'
-
Evercore Says Cerevel Therapeutics Holdings (CERE) BP Results are 'Very Positive'
-
Bausch Health (BHC): FDA Added Extra Hurdle for Generic Xifaxan - Evercore ISI
-
Inspirna to Present at the Evercore ISI Annual HealthCONx Conference
-
Evercore ISI Recognized as the Top-Ranked Firm in U.S. Equity Research
-
UPDATE: Evercore ISI Downgrades Phathom Pharmaceuticals (PHAT) to In Line
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Moderna (MRNA), BioNTech (BNTX) Hit Session Low Amid Doubt FDA Will Back Vaccine Booster
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021
-
Investors, patients await FDA decision on Biogen Alzheimer's drug due Monday
-
Januvia IP an under-the-radar catalyst for Merck (MRK) - Evercore ISI
-
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
-
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
-
Evercore ISI Starts Atea Pharmaceuticals (AVIR) at Outperform
-
RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences
-
Evercore ISI Starts Arcus Biosciences (RCUS) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Evercore ISI Upgrades Amgen (AMGN) to Outperform
-
Evercore ISI Starts Phathom Pharmaceuticals (PHAT) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Evercore's former famed biotech analyst Mark Schoenebaum has passed away
-
Evercore ISI Downgrades Teva Pharma (TEVA) to In Line
-
UPDATE: Evercore ISI Upgrades Dova Pharmaceuticals Inc (DOVA) to Outperform
-
UPDATE: Allergan (AGN) Sees Mid-Day Gains
-
Macrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISI
-
Evercore ISI Downgrades Amgen (AMGN) to In Line
-
Ravi Mehrotra Joins Evercore ISI Research Team
-
Evercore ISI Starts Molecular Templates (MTEM) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Pre-Open Movers 08/24: (ADSK) (SPLK) (BKE) (NFLX) Higher; (HIBB) (GPS) (ROST) Lower (more...)
-
Evercore ISI Upgrades Mylan (MYL) to Outperform
-
Teva Pharma (TEVA) Confident in Branded Business Trends, No Plans to Raise Equity - Evercore ISI
